NBY NovaBay Pharmaceuticals, Inc.

Pharmaceutical Preparations DE CIK: 0001389545
AI RATING
STRONG_SELL
95% Confidence

Investment Thesis

Stablecoin Development Corp exhibits terminal financial distress with negative stockholders' equity of -$23.2M, indicating technical insolvency. The company is burning $8.4M annually in operating losses against only $521K in declining revenue, creating a fundamentally unsustainable business model that will exhaust its $8M cash reserve within 12 months absent significant operational transformation or external capital injection.

Strengths

  • + Maintains $8.0M cash reserve providing short-term liquidity buffer
  • + Minimal capital expenditure requirements ($0) reduces ongoing investment needs
  • + Recent insider activity suggests management engagement despite distress

Risks

  • ! Negative stockholders' equity of -$23.2M represents technical insolvency with liabilities exceeding assets by $22.9M
  • ! Operating cash burn of -$8.4M annually against $521K revenue is mathematically unsustainable; cash runway approximately 12 months
  • ! Gross margin of 8.1% indicates severe operational inefficiency; unit economics appear broken
  • ! Revenue declining 6.4% YoY demonstrates deteriorating market traction or demand
  • ! Massive net losses (-$22.1M) and operating losses (-$8.4M) on minimal revenue base signal fundamental business model failure
  • ! EPS improvement amid revenue decline and increased losses suggests dilutive capital raises likely

Key Metrics to Watch

Financial Metrics

Revenue
521.0K
Net Income
-22.1M
EPS (Diluted)
$0.76
Free Cash Flow
-8.4M
Total Assets
9.0M
Cash
8.0M

Profitability Ratios

Gross Margin 8.1%
Operating Margin -1,619.8%
Net Margin -4,249.7%
ROE N/A
ROA -245.1%
FCF Margin -1,618.0%

Balance Sheet & Liquidity

Current Ratio
7.60x
Quick Ratio
7.19x
Debt/Equity
N/A
Debt/Assets
352.6%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-04-13T02:06:21.897927 | Data as of: 2025-12-31 | Powered by Claude AI